832-497-2220 [email protected]

News and Blog

»News and Blog

Inventory | Non-small cell lung cancer targeted therapies

Lung cancer is one of the most common kinds of malignant tumors in the world. In 2018, there were nearly 2.1 million newly diagnosed lung cancer cases worldwide and 1.76 million deaths. In 2015, there were about 787,000 new lung cancer cases and 631,000 deaths in China alone. Lung cancer has become the first cause of death from malignant tumors in China’s urban population.

Non-small cell lung cancer (NSCLC) accounts for 80-85% of all lung cancer cases. About 20% of newly diagnosed NSCLC patients are early stage, about 25% are locally advanced, and 55% have developed distant metastases. The 5-year survival rate of NSCLC patients is very low.

China Antidepressant Market Review and Opportunity Analysis

According to Baidu’s “2020 Civil War “Illustration”-Baidu Mental Health Day Search Big Data”, under the influence of the COVID-19 epidemic, the search for psychological assistance-related content has reached the highest level of the last decade. The search to find treatments for depression has increased by 69%, and the search for depression-related content this year has increased by 59% compared with 2019. During the epidemic, young working women in China aged 30+ are facing two major causes of anxiety: postpartum depression and issues in the workplace.

Top-tier Chinese Pharmaceutical company profile: Huadong Medicine

Huadong Medicine was established in 1993 and is headquartered in Hangzhou, Zhejiang. It is a large-scale comprehensive listed pharmaceutical company integrating R&D, manufacturing and sales, modern logistics, the healthcare industry, and aesthetic products (stock code: 000963). The company has been selected as one of the Fortune China Top 500 company many times. It has also been awarded the “Top 50 Best Listed Companies in the Asia Pacific” by Forbes three times.

Industry Research | Global Trends and Drug Development for Depression

According to conservative estimates of the World Health Organization, 350 million people worldwide suffer from depression. Unlike short-term mood swings, the symptoms for depression must be present for at least two weeks. Symptoms include, but are not limited to, persistent sadness or anxiety, feelings of hopelessness or pessimism, irritability, loss of interest or pleasure in hobbies or activities, decreased energy or fatigue, and difficulty sleeping. For patients diagnosed with depression, drug intervention is one of the most important treatment approaches.

Magpie Pharmaceuticals develops the only new ALS drug in China

Masitinib mesylate was developed by AB Science. Its clinical indications include amyotrophic lateral sclerosis (ALS), Alzheimer’s (AD), mastocytosis, pancreatic cancer, multiple sclerosis, asthma, prostate cancer, and others. Among them, a new drug application for ALS was submitted to the US FDA in 2019. Masitinib mesylate had previously obtained orphan drug designation for the treatment of pancreatic cancer and amyotrophic lateral sclerosis in 2009 and 2015, respectively.

The Global Market of Age-related Macular Degeneration Exceeds Tens of Billions of Dollars

Age-related macular degeneration (AMD) is a serious and irreversible cause of visual impairment. It is also a leading cause of blindness among the elderly. As populations in China and around the world age, it is estimated that the number of cases worldwide will increase to 288 million by 2040. There are huge unmet clinical needs in the field. Preparations to treat vascular endothelial growth factor (VEGF) are currently the first-line treatment for AMD. Such drugs have shown to be likely to reduce the chance of blindness in neovascular AMD. This article briefly introduces the AMD market and clinical research on VEGF inhibitors with the purpose of providing some potential direction for drug research and development in this field in China.

Note: cover photo source John Hopkins Medicine

Industry Research | Is a cure for Hepatitis B in the near future?

The history of human existence and development has also been a history of struggle against viruses. With recent outbreaks of SARS in 2003, MERS in 2012, or the current novel coronavirus in 2020, again and again there is an emphasis on the importance of antiviral drug development.

The global anti-virus market has reached more than US$270 billion in the past five years. Drugs to target hepatitis B and C comprise very important markets.

Top-tier Chinese Pharmaceutical company profile: Tasly Holding Group

Incorporated in 1994, Tasly Holding Group has since developed into an international and high-tech cooperation, engaging in the pan-health industry with the biological medicine industry as the core business, while the healthcare industry and medical services serve as the two supporting businesses.

Industry Research | China’s Top 10 Drugs to Treat Neurological Diseases

At the moment when venture capital funds are active in the field of biomedicine, oncology drug research and development companies have sprung up, but the CNS sector has received relatively little attention. The pace of life of contemporary people is getting faster and faster, pressure from work is increasing, and the incidence of mental illnesses such as insomnia, anxiety, and depression is also on the rise. MyBioGate will focus on research on neurological drugs this month. We will also review the market and investment opportunities in China and abroad, especially drugs that target the central nervous system (CNS).